413 related articles for article (PubMed ID: 32266832)
1. Factors Associated With the Choice of Oral Anticoagulant Class in the Older Patients: An Observational Study.
Pagès A; Sabatier R; Sallerin B
J Cardiovasc Pharmacol Ther; 2020 Jul; 25(4):332-337. PubMed ID: 32266832
[TBL] [Abstract][Full Text] [Related]
2. Direct Anticoagulants Versus Vitamin K Antagonists in Patients Aged 80 Years or Older With Atrial Fibrillation in a "Real-world" Nationwide Registry: Insights From the FANTASIIA Study.
Ortiz MR; Muñiz J; Esteve-Pastor MA; Marín F; Roldán I; Cequier A; Martínez-Sellés M; Saldivar HG; Bertomeu V; Anguita M
J Cardiovasc Pharmacol Ther; 2020 Jul; 25(4):316-323. PubMed ID: 32228180
[TBL] [Abstract][Full Text] [Related]
3. Apixaban in the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation in France: Rationale and design of the PAROS cross-sectional study.
Picard F; Ducrocq G; Danchin N; Falissard B; Hanon O; Mahe I; Touzé E; Steg PG
Arch Cardiovasc Dis; 2018 May; 111(5):349-356. PubMed ID: 29191525
[TBL] [Abstract][Full Text] [Related]
4. Appropriateness of direct oral anticoagulant prescribing in older subjects with atrial fibrillation discharged from acute medical wards.
De Vincentis A; Soraci L; Arena E; Sciacqua A; Armentaro G; Aucella F; Corsonello A; Aucella F; Antonelli Incalzi R
Br J Clin Pharmacol; 2024 May; 90(5):1231-1239. PubMed ID: 38321367
[TBL] [Abstract][Full Text] [Related]
5. PrevAleNce and Associated factors of inappropriaTe dosing of direct Oral anticoaguLants In pAtients with Atrial Fibrillation: the ANATOLIA-AF Study.
Kocabaş U; Ergin I; Yavuz V; Murat S; Özdemir I; Genç Ö; Altın C; Tüner H; Meriç BK; Çoner A; Yüce Eİ; Boyraz B; Aslan O; Dal A; Şen T; İbişoğlu E; Erdoğan A; Özgeyik M; Demir M; Bilgel ZG; Şengör BG; Urgun ÖD; Doğduş M; Tekin DDN; Çakal S; Çayırlı S; Güler A; Karabulut D; Dalgıç O; Uzman O; Murat B; Şahin Ş; Karabulut U; Kıvrak T; Coşgun MS; Özyurtlu F; Kaplan M; Özçalık E;
Cardiovasc Drugs Ther; 2024 Jun; 38(3):581-599. PubMed ID: 36527566
[TBL] [Abstract][Full Text] [Related]
6. Apixaban for prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation in France: The PAROS cross-sectional study of routine clinical practice.
Falissard B; Picard F; Mahe I; Hanon O; Touzé E; Danchin N; Lamy FX; Ricci L; Steg PG
Arch Cardiovasc Dis; 2019; 112(6-7):400-409. PubMed ID: 31014991
[TBL] [Abstract][Full Text] [Related]
7. Utilization of oral anticoagulants in Korean nonvalvular atrial fibrillation patients.
Song HY; Son KB; Shin JY; Bae S
Int J Clin Pharm; 2019 Dec; 41(6):1434-1441. PubMed ID: 31522377
[TBL] [Abstract][Full Text] [Related]
8. Choice of New Oral Anticoagulant Agents Versus Vitamin K Antagonists in Atrial Fibrillation: FANTASIIA Study.
Moreno-Arribas J; Bertomeu-González V; Anguita-Sanchez M; Cequier Á; Muñiz J; Castillo J; Sanchis J; Roldán I; Marín F; Bertomeu-Martínez V;
J Cardiovasc Pharmacol Ther; 2016 Mar; 21(2):150-6. PubMed ID: 26229096
[TBL] [Abstract][Full Text] [Related]
9. Rates of Potentially Inappropriate Dosing of Direct-Acting Oral Anticoagulants and Associations With Geriatric Conditions Among Older Patients With Atrial Fibrillation: The SAGE-AF Study.
Sanghai S; Wong C; Wang Z; Clive P; Tran W; Waring M; Goldberg R; Hayward R; Saczynski JS; McManus DD
J Am Heart Assoc; 2020 Mar; 9(6):e014108. PubMed ID: 32146898
[TBL] [Abstract][Full Text] [Related]
10. Nonvitamin K Antagonist Oral Anticoagulants Versus Warfarin in Atrial Fibrillation Patients and Risk of Dementia: A Nationwide Propensity-Weighted Cohort Study.
Søgaard M; Skjøth F; Jensen M; Kjældgaard JN; Lip GYH; Larsen TB; Nielsen PB
J Am Heart Assoc; 2019 Jun; 8(11):e011358. PubMed ID: 31138001
[TBL] [Abstract][Full Text] [Related]
11. Current status and factors influencing oral anticoagulant therapy among patients with non-valvular atrial fibrillation in Jiangsu province, China: a multi-center, cross-sectional study.
Liu T; Yang HL; Gu L; Hui J; Omorogieva O; Ren MX; Wang XH
BMC Cardiovasc Disord; 2020 Jan; 20(1):22. PubMed ID: 31948390
[TBL] [Abstract][Full Text] [Related]
12. Use of Direct Oral Anticoagulants in Canadian Primary Care Practice 2010-2015: A Cohort Study From the Canadian Primary Care Sentinel Surveillance Network.
McAlister FA; Garrison S; Kosowan L; Ezekowitz JA; Singer A
J Am Heart Assoc; 2018 Jan; 7(3):. PubMed ID: 29374047
[TBL] [Abstract][Full Text] [Related]
13. Novel Oral Anticoagulant Based Versus Vitamin K Antagonist Based Double Therapy Among Stented Patients With Atrial Fibrillation: Insights From the PIONEER AF-PCI Trial.
Kerneis M; Yee MK; Mehran R; Nafee T; Bode C; Halperin JL; Peterson ED; Verheugt FWA; Wildgoose P; van Eickels M; Lip GYH; Cohen M; Fox KAA; Gibson CM
Circ Cardiovasc Interv; 2019 Nov; 12(11):e008160. PubMed ID: 31707805
[TBL] [Abstract][Full Text] [Related]
14. Is the prescription right? A review of non-vitamin K antagonist anticoagulant (NOAC) prescriptions in patients with non-valvular atrial fibrillation. Safe prescribing in atrial fibrillation and evaluation of non-vitamin K oral anticoagulants in stroke prevention (SAFE-NOACS) group.
Pharithi RB; Ranganathan D; O'Brien J; Egom EE; Burke C; Ryan D; McAuliffe C; Vaughan M; Coughlan T; Morrissey E; McHugh J; Moore D; Collins R
Ir J Med Sci; 2019 Feb; 188(1):101-108. PubMed ID: 29860595
[TBL] [Abstract][Full Text] [Related]
15. Female Sex as a Thromboembolic Risk Factor in the Era of Nonvitamin K Antagonist Oral Anticoagulants.
Gallù M; Marrone G; Legramante JM; De Lorenzo A; Di Daniele N; Noce A
Cardiovasc Ther; 2020; 2020():1743927. PubMed ID: 32684980
[TBL] [Abstract][Full Text] [Related]
16. Death rates and causes in anticoagulated atrial fibrillation patients: a population-based study.
Denas G; Fedeli U; Gennaro N; Ferroni E; Corti MC; Pengo V
J Cardiovasc Med (Hagerstown); 2020 Jun; 21(6):415-419. PubMed ID: 32355064
[TBL] [Abstract][Full Text] [Related]
17. Patients with non-valvular atrial fibrillation on vitamin k antagonists or direct-acting oral anticoagulants: patients profile and long-term follow up outcomes.
Sigismondi A; Camacho-Freire SJ; León-Jiménez J; Isasti-Aizpurva G; García-Lizana MD; Morgado-García de Polavieja JI; Caro-Fernández FJ; Roa-Garrido J; Navarro-Roldán F; Díaz-Fernández JF
Arch Cardiol Mex; 2019; 89(4):382-392. PubMed ID: 31834326
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF).
Halperin JL; Hankey GJ; Wojdyla DM; Piccini JP; Lokhnygina Y; Patel MR; Breithardt G; Singer DE; Becker RC; Hacke W; Paolini JF; Nessel CC; Mahaffey KW; Califf RM; Fox KA;
Circulation; 2014 Jul; 130(2):138-46. PubMed ID: 24895454
[TBL] [Abstract][Full Text] [Related]
19. [Factors Associated with Direct Oral Anticoagulants versus Vitamin K Antagonists in Patients with Non-valvular Atrial Fibrillation].
Saliba L; Mondoly P; Duparc A; Bura-Rivière A; Maury P; Calmels V; Sallerin B; Pathak A; Montastruc JL; Bagheri H
Therapie; 2015; 70(6):485-92. PubMed ID: 26223162
[TBL] [Abstract][Full Text] [Related]
20. Risk of stroke in patients with prior VKA or DOAC: A population-based real-world registry analysis.
Mayer-Suess L; Rinner H; Lang W; Greisenegger S; Mikšová D; Gattringer T; Enzigner C; Sykora M; Vosko M; Mutzenbach JS; Ferrari J; Kiechl S; Knoflach M;
Eur Stroke J; 2024 Jun; 9(2):418-423. PubMed ID: 38161290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
